Securities – Fraud – Clinical trials

United States District Court

September 19, 2022

When a securities fraud complaint was filed alleging that investors were misled about the defendant biopharmaceutical company’s fledgling Alzheimer’s disease drug, the complaint must be dismissed because (1) the plaintiffs failed to allege facts sufficient to show that the statements at issue were false or misleading, (2) plaintiffs failed to sufficiently plead scienter, …


Previous Investors pour $8.6 billion into supply chain tech startups
Next 3 reasons to spend on a personal loan this year